Austria

The information below comes from the AGES medical market control database (in German: https://aspregister.basg.gv.at/aspregister/faces/aspregister.jspx). The database contains only data on the availability of the drug in the country. No further information on reimbursement mechanisms is provided for certain requirements.

Active Substance Indication Availability and Reimbursement Comments
Bevacizumab Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Available, currently researching information on reinbursement https://aspregister.basg.gv.at/aspregister/faces/aspregister.jspx
Blinatumomab Precursor Cell Lymphoblastic Leukemia-Lymphoma Available, currently researching information on reinbursement https://aspregister.basg.gv.at/aspregister/faces/aspregister.jspx
Brentuximab vedotin Hodgkin Disease Lymphoma, Non-Hodgkin Available, currently researching information on reinbursement For more information visit:https://aspregister.basg.gv.at/aspregister/faces/aspregister.jspx
Daratumumab Multiple Myeloma Available, currently researching information on reinbursement For more information visit: https://aspregister.basg.gv.at/aspregister/faces/aspregister.jspx
Elotuzumab Multiple Myeloma Available, currently researching information on reinbursement For more information visit: https://aspregister.basg.gv.at/aspregister/faces/aspregister.jspx
Inotuzumab ozogamicin Acute lymphoblastic leukaemia (recommended, but not approved yet) Currently researching information For more information visit: https://aspregister.basg.gv.at/aspregister/faces/aspregister.jspx
Ipilimumab Melanoma Available and reinbursed For more information visit: https://aspregister.basg.gv.at/aspregister/faces/aspregister.jspx
Nivolumab Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Urotherial carcinoma (recommended, but not approved yet) Available and reinbursed For more information visit: https://aspregister.basg.gv.at/aspregister/faces/aspregister.jspx
Obinutuzumab Leukemia, Lymphocytic, Chronic, B-Cell Available, currently researching information on reinbursement For more information visit: https://aspregister.basg.gv.at/aspregister/faces/aspregister.jspx
Ofatumumab Leukemia, Lymphocytic, Chronic, B-Cell Available, currently researching information on reinbursement For more information visit: https://aspregister.basg.gv.at/aspregister/faces/aspregister.jspx
Olaratumab Sarcoma Available, currently researching information on reinbursement For more information visit: https://aspregister.basg.gv.at/aspregister/faces/aspregister.jspx
Pembrolizumab Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available, currently researching information on reinbursement For more information visit: https://aspregister.basg.gv.at/aspregister/faces/aspregister.jspx
Rituximab Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available, currently researching information on reinbursement For more information visit: https://aspregister.basg.gv.at/aspregister/faces/aspregister.jspx
Talimogene laherparepvec (t-vec) Melanoma Available, currently researching information on reinbursement For more information visit: https://aspregister.basg.gv.at/aspregister/faces/aspregister.jspx

DISCLAIMER1: This website is intended for informative purposes only, and it does not create any rights. The information displayed in this website has been obtained from publicly available sources and collected by the European Cancer Patient Coalition, Specific restrictions, lack of information on availability and/or reimbursement may exist, even depending on indications or doses, and may vary between countries. Medicines may also be used for indications other than those officially authorised by the European Medicines Agency, and may also be prescribed off-label, depending on the doctor's advice or hospital practice. Final reimbursement quantities and conditions may also depend on applicable insurance schemes or hospital practices. If you have been diagnosed with cancer, please always check with your doctor and healthcare provider to confirm the specific conditions applying to your situation.